Dr. Keng's research focus is on clinical trials in hematologic malignancies, including myelodysplastic syndromes and leukemias. He has a special interest in treating the elderly population, determining optimal combinations and timing of targeted agents in MDS and leukemia, and studying patient safety and quality improvement.
Get the latest thought leadership on AML delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.
Thanks to our HealthTree Community for AML Sponsors:
%20-%20smaller%20jpg_5093a115-769d-4cb8-99c4-e07244874f4d.jpg?alt=media){kind=logo}
Follow Us
Terms of Use and Privacy Policy Newsroom About Donations Find an AML Specialist Newsletter Learn Connect
Copyright © 2022 HealthTree Foundation. All Rights Reserved.
The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811
